Rain Therapeutics to Participate in H.C. Wainwright’s 3rd Annual Precision Oncology Virtual Conference

Rhea-AI Summary

Rain Therapeutics (NasdaqGS: RAIN) announced participation in the H.C. Wainwright’s 3rd Annual Precision Oncology Conference on November 14, 2022. The company’s management will engage in one-on-one investor meetings, with CEO Avanish Vellanki featured in a fireside chat at 1:00 PM ET. Rain is focused on developing precision oncology therapeutics, including its lead candidate milademetan, an oral small molecule that reactivates p53 by inhibiting the MDM2-p53 complex. The company is also advancing a preclinical program targeting RAD52.

NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in H.C. Wainwright’s 3^rd Annual Precision Oncology Conference on November 14, 2022.

Company management will participate in one-on-one investor meetings, and Avanish Vellanki, CEO, will be participating in a fireside chat on Monday, November 14 at 1:00 PM ET. The webcast of the fireside chat is linked here.

If you would like to request a meeting with management, please contact your H.C. Wainwright representative.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

FAQ

What is the significance of Rain Therapeutics participating in the H.C. Wainwright’s 3rd Annual Precision Oncology Conference?

Rain Therapeutics is showcasing its advancements in precision oncology and its lead product candidate, milademetan, at the conference.

Who is representing Rain Therapeutics at the conference on November 14, 2022?

CEO Avanish Vellanki will represent Rain Therapeutics and participate in a fireside chat.

What is milademetan and its role in Rain Therapeutics' research?

Milademetan is an oral small molecule that inhibits the MDM2-p53 complex, reactivating p53 to target cancer cells.

What is the focus of Rain Therapeutics' preclinical program?

The preclinical program aims to induce synthetic lethality in cancer cells by inhibiting RAD52.

How can investors request a meeting with Rain Therapeutics management during the conference?

Investors can contact their H.C. Wainwright representative to request a meeting.